skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer



Review

(3355) Total Article Views


Authors: Solanki AA, Liauw SL

Published Date June 2011 Volume 2011:3 Pages 95 - 104
DOI: http://dx.doi.org/10.2147/RRU.S14245

Abhishek A Solanki, Stanley L Liauw
Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, IL, USA

Abstract: Brachytherapy and external beam radiotherapy are effective and commonly used treatment modalities in men with localized prostate cancer. In this review, we explore the role of radiation therapy in the curative management of prostate cancer, including the use of conformal therapeutic techniques to allow for the escalation of radiation doses to tumor, along with the use of combined radiation and hormonal therapy to enhance disease outcomes in men with aggressive disease. We also review the possible anticancer role of HMG-CoA reductase inhibiting agents (statins) in men with prostate cancer. Laboratory evidence suggests that statins may have antineoplastic effects when used alone and may sensitize cells to radiation therapy when given in combination. We explore the biologic basis for an anticancer effect and the clinical evidence suggesting statins may aid in improving outcomes with radiation therapy for localized prostate cancer.

Keywords:
HMG-CoA reductase inhibitors, statins, radiotherapy, prostate cancer


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Stanley Liauw


Readers of this article also read: